Abstract
A 65-year-old male with liver metastases after lung cancer resection was treated with five courses of chemotherapy consisting of gemcitabine (GEM) 1,000 mg/m2 (day 1, 8, every 4 weeks) plus carboplatin (CBDCA) AUC 6 (day 1, every 4 weeks). A partial response (PR) was achieved, his symptoms abated and his quality of life(QOL) improved. Although bone marrow suppression was observed as a side effect, it was within the tolerable range and did not interfere with therapy. This approach may be worth considering as a first-line anti-cancer chemotherapy for recurrence lung cancer.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / administration & dosage
-
Carcinoma, Small Cell / drug therapy
-
Carcinoma, Small Cell / secondary*
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Drug Administration Schedule
-
Gemcitabine
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary*
-
Lung Neoplasms / pathology*
-
Lung Neoplasms / surgery
-
Lymph Node Excision
-
Male
-
Pneumonectomy*
-
Postoperative Period
-
Quality of Life
Substances
-
Deoxycytidine
-
Carboplatin
-
Gemcitabine